Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
167
datasets available to search
ShareScore release 0.9.0
Dataset results
167 results for “myotonic dystrophy”
Myotonic Dystrophy Type 1 Aerobic Exercise Study
ClinicalTrials.gov study NCT04187482. IPD Sharing: NO. Countries: 1. Publications: 1.
Arrhythmias in Myotonic Muscular Dystrophy
ClinicalTrials.gov study NCT00622453. IPD Sharing: Not stated. Countries: 1. Publications: 6.
Venous Thromboembolism in Myotonic Dystrophy Type 1
ClinicalTrials.gov study NCT03424460. IPD Sharing: UNDECIDED. Countries: 1. Publications: 26.
A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1
ClinicalTrials.gov study NCT02312011. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Remote Physical Activity Program in the Population Suffering from Type 1 Myotonic Dystrophy
ClinicalTrials.gov study NCT05072288. IPD Sharing: NO. Countries: 1. Publications: 16.
Extracellular RNA Biomarkers of Myotonic Dystrophy
ClinicalTrials.gov study NCT05020002. IPD Sharing: NO. Countries: 1. Publications: 2.
Profile of Dysphagia in Myotonic Dystrophy Type 1 (DM1)
ClinicalTrials.gov study NCT05865483. IPD Sharing: NO. Countries: 1. Publications: 1.
Methylphenidate in Myotonic Dystrophy Type 1
ClinicalTrials.gov study NCT01421992. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Poor Neck Proprioception May Cause Balance Deficits in Myotonic Dystrophy 1
ClinicalTrials.gov study NCT04712422. IPD Sharing: YES. Countries: 1. Publications: 16.
Clinical Outcome Measures in Myotonic Dystrophy Type 2
ClinicalTrials.gov study NCT03603171. IPD Sharing: UNDECIDED. Countries: 1. Publications: 5.
Data from: Genetic determinants of disease severity in the myotonic dystrophy type 1 OPTIMISTIC cohort
Open the record for dataset details and reuse information.
Supplemental material from: A population-based prevalence of myotonic dystrophy type 1
Open the record for dataset details and reuse information.
Data from: Intra-Rater reliability and validity of outcome measures in Myotonic Dystrophy Type 1
<p>Objective</p> <p>To investigate intra-rater reliability, concurrent- and construct validity of muscle strength, balance, and functional mobility measures in individuals with non-congenital DM1.</p> <p>Methods</p> <p><a name="_Hlk4397329">Seventy-eight adults with non-congenital DM1 participated in visit 1 and 73 of the subjects participated in visit 2 separated by 1-2 weeks. The assessments consisted of </a>muscle strength tests with Hand-Held Dynamometry (HHD) and Stationary Dynamometry in the lower limb. The balance tests comprised of Step Test, Timed Up and Go test, Feet-Together stance, Tandem-Stance, One-Leg-Stance, and modified Clinical Test of Sensory Integration and Balance on a balance platform. The functional mobility tests consisted of the 10-meter Walk Test (10mWT) and 10-times Sit-To-Stand test.</p> <p><a name="_Hlk14169462">Results</a></p> <p>The HHD and Stationary Dynamometry were sufficiently intra-rater reliable for most muscle groups on a group- (SEM<sub>%</sub>≤15%) and individual level (MDD<sub>95%</sub>≤30%), but HHD was most reliable. Stationary Dynamometry measured a higher torque than HHD for all extensor muscles, but for single individuals none of the devices were favored. Overall, intra-rater reliability and validity were only sufficient for the dynamic balance tests and not the static balance tests. Both functional mobility tests were sufficiently reliable and valid, but the 10mWT was most reliable.</p> <p>Conclusion</p> <p>Overall, HHD is recommended as a reliable and valid tool for single individuals and for flexor muscles on a group level. For balance assessments, the dynamic balance tests are recommended as the most valid and reliable balance tests. Both functional mobility tests are recommended for valid and reliable outcomes, but the 10mWT was superior for reliability.</p>
Data from: Lower extremity muscle pathology in myotonic dystrophy type 1 assessed by quantitative MRI
Objective: To determine the value of quantitative MRI to provide imaging biomarkers for disease in 20 different upper and lower leg muscles of myotonic dystrophy type 1 (DM1) patients. Methods: We acquired images covering these muscles in 33 genetically and clinically well-characterized DM1 patients and 10 unaffected controls. MR images were recorded with a Dixon method to determine muscle fat fraction, muscle volume and contractile muscle volume, and a multi-spin echo sequence to determine T2 water relaxation time (T2water), reflecting putative oedema. Results: Muscles in DM1 patients had higher fat fractions than muscles of controls (15.6%±11.1% vs. 3.7%±1.5%). Also, patients had smaller muscle volumes (902±232 cm3 vs. 1097±251 cm3), contractile muscle volumes (779±247 cm3 vs. 1054±246 cm3), and increased T2water (33.4±1.0 ms vs. 31.9±0.6 ms), indicating atrophy and oedema, respectively. Lower leg muscles were affected most frequently, especially the gastrocnemius medialis and soleus. Distribution of fat content per muscle indicated gradual fat infiltration in DM1. Between-patient variation in fat fraction was explained by age (~45%), and another ~14% by estimated progenitor CTG repeat length (r2 = 0.485) and somatic instability (r2 = 0.590). Fat fraction correlated with the six-minute walk test (r = -0.553) and muscular impairment rating scale (r = 0.537), and revealed subclinical muscle involvement. Conclusion: This cross-sectional quantitative MRI study of 20 different lower extremity muscles in DM1 patients revealed abnormal values for muscle fat fraction, volume and T2water, which therefore may serve as objective biomarkers to assess disease state of skeletal muscles in these patients.
Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1
ClinicalTrials.gov study NCT03959189. IPD Sharing: NO. Countries: 1. Publications: 0.
Cardiovascular Consequences of NIV Withdrawal in Patients With Myotonic Dystrophy
ClinicalTrials.gov study NCT00745238. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy
ClinicalTrials.gov study NCT03692312. IPD Sharing: Not stated. Countries: 5. Publications: 0.
Music Intervention for Brain-Heart Disease in Myotonic Dystrophy Type 1 (DM1)
ClinicalTrials.gov study NCT06809049. IPD Sharing: YES. Countries: 1. Publications: 0.
Brain Involvement in Myotonic Dystrophy Type I: From Functional Neuroimaging to the Impact on Quality of Life
ClinicalTrials.gov study NCT03589677. IPD Sharing: NO. Countries: 0. Publications: 21.
Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1
ClinicalTrials.gov study NCT00577577. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.